Host genetic determinants of Neisseria meningitidis infections

Lancet Infectious Diseases

Volumn 3, Issue 9, 2003, Pages 565-577

  Emonts, M ^a   Hazelzet, J A ^b   De Groot, R ^b   Hermans, P W M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; DIPEPTIDYL CARBOXYPEPTIDASE; FC RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MANNOSE BINDING PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROPERDIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

BACTERIAL MENINGITIS; COMPLEMENT ACTIVATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HOST SUSCEPTIBILITY; HUMAN; IMMUNITY; NEISSERIA MENINGITIDIS; NONHUMAN; OPSONIZATION; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 0042362250     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(03)00740-0     Document Type: Review

References (84)

1. Rich RR, Fleisher TA, Shearer WT, Kotzin, BL, Schroeder Jr, HW, eds. Clinical immunology principles and practice, 2nd edn. St Louis: Mosby; 2001.
2. Bauer S, Kirschning CJ, Hacker H, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA 2001; 98:9237-42.
3. Datta SK, Redecke V, Prilliman KR, et al. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol 2003; 170:4102-10,
4. Kornelisse RF, de Groot R, Neijens HJ. Bacterial meningitis: mechanisms of disease and therapy. Eur J Pediatr 1995; 154:85-96.
5. de Kleijn ED, Hazelzet JA, Kornelisse RF, de Groot R. Pathophysiology of meningococcal sepsis in children. Eur J Pediatr 1998; 157:869-80.
6. Haralambous E, Weiss H, Radalowicz A, Hibberd M, Booy R, Levin M. Sibling familial risk ratio of meningococcal disease in UK Caucasians. Epidemiol Infect (in press).
7. Smirnova I, Mann N, Dols A, et al. Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility. Proc Natl Acad Sci USA 2003; 100:6075-80.
8. Read RC, Pullin J, Gregory S, et al. A functional polymorphism of toll-like receptor 4 is not associated with likelihood or severity of meningococcal disease. J Infect Dis 2001; 184: 640-42.
9. Hubacek JA, Stuber F, Frohlich D, et al. Gene variants of the bactericidal/permeability increasing protein and lipopolysaccharide binding protein in sepsis patients: gender-specific genetic predisposition to sepsis. Crit Care Med 2001; 29: 557-61.
10. Harding D, Baines PB, Brull D, Vassiliou V, Ellis I, Hart A, et al. Severity of meningococcal disease in children and the angiotensin-converting enzyme insertion/deletion polymorphism. Am J Respir Crit Care Med 2002; 165:1103-06.
11. Hibberd ML, Sumiya M, Summerfield JA, Booy R, Levin M. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Meningococcal Research Group. Lancet 1999; 353:1049-53.
12. Fijen CA, Kuijper EJ, te Bulte MT, Daha MR, Dankert J. Assessment of complement deficiency in patients with meningococcal disease in The Netherlands. Clin Infect Dis 1999; 28:98-105.
13. Biesma DH, Hannema AJ, van Velzen-Blad H, et al. A family with complement factor D deficiency. J Clin Invest 2001; 108:233-40.
14. van der Pol WL, Huizinga TW, Vidarsson G, et al. Relevance of Fc gamma receptor and interleukin-10 polymorphisms for meningococcal disease. J Infect Dis 2001; 184:1548-55.
15. Domingo P, Muniz-Diaz E, Baraldes MA, et al. Associations between Fc gamma receptor IIA polymorphisms and the risk and prognosis of meningococcal disease. Am J Med 2002; 112:19-25.
16. Bredius RG, Derkx BH, Fijen CA, et al. Fc gamma receptor IIa (CD32) polymorphism in fulminant meningococcal septic shock in children. J Infect Dis 1994; 170:848-53.
17. Platonov AE, Kuijper EJ, Vershinina IV, et al. Meningococcal disease and polymorphism of Fc gamma RIIa (CD32) in late complement component-deficient individuals. Clin Exp Immunol 1998; 111:97-101.
18. Fijen CA, Bredius RG, Kuijper EJ. Polymorphism of IgG Fc receptors in meningococcal disease. Ann Intern Med 1993; 119:636.
19. Fijen CA, Bredius RG, Kuijper EJ, et al. The role of Fc gamma receptor polymorphisms and C3 in the immune defence against Neisseria meningitidis in complement-deficient individuals. Clin Exp Immunol 2000; 120:338-45.
20. Kondaveeti S, Hibberd ML, Levin M. The insertion/deletion polymorphism in the t-PA gene does not significantly affect outcome of meningococcal disease. Thromb Haemost 1999; 82: 161-62.
21. Hermans PW, Hibberd ML, Booy R, et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 1999; 354:556-60.
22. Westendorp RG, Hottenga JJ, Slagboom PE. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 1999; 354:561-53.
23. Haralambous E, Hibberd M, Ninis N, Hermans P, Nadel E, Levin M. The role of the functional plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism in susceptibility, severity and outcome of meningococcal disease in Caucasian children. Crit Care Med (in press).
24. Kondaveeti S, Hibberd ML, Booy R, Nadel S, Levin M. Effect of the Factor V Leiden mutation on the severity of meningococcal disease. Pediatr Infect Dis J 1999; 18:893-96.
25. Nadel S, Newport MJ, Booy R, Levin M. Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease. J Infect Dis 1996; 174: 878-80.
26. Westendorp RG, Langermans JA, Huizinga TW, et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997; 349: 170-73.
27. Read RC, Camp NJ, di Giovine FS, et al. An interleukin-1 genotype is associated with fatal outcome of meningococcal disease. J Infect Dis 2000; 182:1557-60.
28. Stuber F, Petersen M, Bokelmann F, Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 1996; 24:381-84.
29. Fang XM, Schroder S, Hoeft A, Stuber F. Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med 1999; 27:1330-34.
30. Balding J, Livingstone WJ, Healy M, et al. G to C transition in the promoter region of the IL6 gene is associated with disease outcome in meningococcal sepsis (abstract). XVIII International Society on Thrombosis and Haemostasis; Paris, France; 2001. P1065.
31. Schluter B, Raufhake C, Erren M, et al. Effect of the interleukin-6 promoter polymorphism (-174 G/C) on the incidence and outcome of sepsis. Crit Care Med 2002; 30:32-37.
32. Carrol ED, Mobbs KJ, Thomson AP, Hart CA. Variable number tandem repeat polymorphism of the interleukin-1 receptor antagonist gene in meningococcal disease. Clin Infect Dis 2002; 35: 495-97.
33. Read RC, Cannings C, Naylor SC, et al. Variation within genes encoding interleukin-1 and the interleukin-1 receptor antagonist influence the severity of meningococcal disease. Ann Intern Med 2003; 138:534-41.
34. Underhill DM, Ozinsky A. Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol 2002; 14:103-10.
35. Akira S. Toll-like receptors and innate immunity. Adv Immunol 2001; 78:1-55.
36. Smirnova I, Hamblin MT, McBride C, Beutler B, Di Rienzo A. Excess of rare amino acid polymorphisms in the Toll-like receptor 4 in humans. Genetics 2001; 158:1657-64.
37. Lazarus R, Klimecki WT, Raby BA, et al. Single-nucleotide polymorphisms in the Toll-like receptor 9 gene (TLR9): frequencies, pairwise linkage disequilibrium, and haplotypes in three US ethnic groups and exploratory case-control disease association studies (small star, filled). Genomics 2003; 81:85-91.
38. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin 1-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86:1343-46.
39. Danser AH, Schalekamp MA, Bax WA, et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 1995; 92:1387-88.
40. Von Depka M, Czwalinna A, Wermes C, et al. The deletion polymorphism in the angiotensin-converting enzyme gene is a moderate risk factor for venous thromboembolism. Thromb Haemost 2003; 89:847-52.
41. Hazelzet JA, de Groot R, van Mierlo G, et al. Complement activation in relation to capillary leakage in children with septic shock and purpura. Infect Immun 1998; 66:5350-56.
42. Hibberd ML, Summerfield JA, Levin M. Variation in the mannose binding lectin (MBL) gene and susceptibility to sepsis. Sepsis 2001; 4:201-07.
43. Madsen HO, Garred P, Kurtzhals JA, et al. A new frequent allele is the missing link in the structural polymorphism of the human mannan-binding protein. Immunogenetics 1994; 40:37-44.
44. Bax WA, Cluysenaer OJ, Bartelink AK, Aerts PC, Ezekowitz RA, van Dijk H. Association of familial deficiency of mannose-binding lectin and meningococcal disease. Lancet 1999; 354:1094-95.
45. Janeway CA, Travers P, Walport M, Shlomchik, eds. Immunobiology: the immune system in health and disease. 5th ed. New York: Garland Publishing; 2001.
46. Goundis D, Holt SM, Boyd Y, Reid KB. Localization of the properdin structural locus to Xp11.23-Xp21-1. Genomics 1989; 5:56-60.
47. Fredrikson GN, Gullstrand B, Westberg J, Sjöholm AG, Uhlen M, Truedsson L. Investigation of properdin expression in monocytes from properdin deficient individuals by intracellular staining and mRNA analysis. Exp Clin Immunogenet 1997; 14:61.
48. Spath PJ, Sjoholm AG, Fredrikson GN, et al. Properdin deficiency in a large Swiss family: identification of a stop codon in the properdin gene, and association of meningococcal disease with lack of the IgG2 allotype marker G2m(n). Clin Exp Immunol 1999; 118:278-84.
49. Westberg J, Fredrikson GN, Truedsson L, Sjoholm AG, Uhlen M. Sequence-based analysis of properdin deficiency: identification of point mutations in two phenotypic forms of an X-linked immunodeficiency. Genomics 1995; 29:1-8.
50. van den Bogaard R, Fijen CA, Schipper MG, de Galan L, Kuijper EJ, Mannens MM. Molecular characterisation of 10 Dutch properdin type I deficient families: mutation analysis and X-inactivation studies. Eur J Hum Genet 2000; 8: 513-18.
51. Fredrikson GN, Westberg J, Kuijper EJ, et al. Molecular characterization of properdin deficiency type III: dysfunction produced by a single point mutation in exon 9 of the structural gene causing a tyrosine to aspartic acid interchange. J Immunol 1996; 157:3666-71.
52. Densen P, Weiler JM, Griffiss JM, Hoffmann LG. Familial properdin deficiency and fatal meningococcemia. Correction of the bactericidal defect by vaccination. N Engl J Med 1987; 316: 922-26.
53. Bjerre A, Brusletto B, Mollnes TE, et al. Complement activation induced by purified Neisseria meningitidis lpopolysaccharide (LPS), outer membrane vesicles, whole bacteria, and an LPS-free mutant. J Infect Dis 2002; 185:220-28.
54. Smith I, Vedeler C, Halstensen A. FcgammaRIIa and FcgammaRIIIb polymorphisms were not associated with meningococcal disease in Western Norway. Epidemiol Infect 2003; 130:193-99.
55. Hazelzet JA, Risseeuw-Appel IM, Kornelisse RF, et al. Age-related differences in outcome and severity of DIC in children with septic shock and purpura. Thromb Haemost 1996; 76:932-38.
56. Eriksson P, Kallin B, van 't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen- activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92:1851-55.
57. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268:10739-45.
58. Kornelisse RF, Hazelzet JA, Savelkoul HF, et al. The relationship between plasminogen activator inhibitor-1 and proinflammatory and counterinflammatory mediators in children with meningococcal septic shock. J Infect Dis 1996; 173: 1148-56.
59. Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001; 345: 408-16.
60. Hazelzet JA, de Kleijn ED, de Groot R. Endothelial protein C activation in meningococcal sepsis. N Engl J Med 2001; 345:1776-77.
61. De Kleijn ED, De Groot R, Hack CE, et al. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: A randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med 2003; 31:1839-47.
62. Yuksel M, Okajima K, Uchiba M, Horiuchi S, Okabe H. Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes. Thromb Haemost 2002; 88:267-73.
63. Hackett SJ, Thomson AP, Hart CA. Cytokines, chemokines and other effector molecules involved in meningococcal disease. J Med Microbiol 2001; 50: 847-59.
64. Westendorp RG, Langermans JA, de Bel CE, et al. Release of tumor necrosis factor: an innate host characteristic that may contribute to the outcome of meningococcal disease. J Infect Dis 1995; 171: 1057-60.
65. Westendorp RG, Langermans JA, Huizinga TW, Verweij CL, Sturk A. Genetic influence on cytokine production in meningococcal disease. Lancet 1997; 349:1912-13.
66. Booy R, Nadel S, Hibberd M, Levin M, Newport MJ. Genetic influence on cytokine production in meningococcal disease. Lancet 1997; 349:1176.
67. Huizinga TW, Westendorp RG, Bollen EL, et al. TNFalpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol 1997; 72: 149-53.
68. Uglialoro AM, Turbay D, Pesavento PA, et al. Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-alpha gene promoter. Tissue Antigens 1998; 52: 359-67.
69. Tarlow JK, Blakemore AI, Lennard A, et al. Polymorphism in human interleukin 1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993; 91:403-04.
70. Clay FE, Tarlow JK, Cork MJ, Cox A, Nicklin MJ, Duff GW. Novel interleukin-1 receptor antagonist exon polymorphisms and their use in allele-specific mRNA assessment. Hum Genet 1996; 97:723-26.
71. Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 2000; 275: 18138-44.
72. van Deventer SJ, Buller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76:2520-26.
73. Latifi SM, Levine AD. Kinetics of interleukin 6 synthesis predictive of outcome in sepsis. Crit Care Med 1999; 27:A102.
74. Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG, Huizinga TW. Interleukin 10 secretion in relation to human interleukin 10 locus haplotypes. Proc Natl Acad Sci USA 1998; 95: 9465-70.
75. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24:1-8.
76. Gibson AW, Edberg JC, Wu J, Westendorp RG, Huizinga TW, Kimberly RP. Novel single nucleotide polymorphisms in the distal interleukin 10 promoter affect interleukin 10 production and enhance the risk of systemic lupus erythematosus. J Immunol 2001; 166:3915-22.
77. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med 1969; 129:1327-48.
78. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969; 129: 1307-26.
79. Griffiss JM, Bannatyne RM, Artenstein MS, Anglin CS. Recurrent meningococcal infection with an antigenically identical strain. JAMA 1974; 229: 68-70.
80. Borrow R. Update on meningococcal C conjugate vaccination programme in the UK. In: 21st meeting, European Society for Paediatric Infectious Diseases; 2003; Giardini Naxos, Sicily; 2003: p 6.
81. Dankert J, Van der Ende A, Spanjaard L. Epidemiology of group C meningococcal disease in the Netherlands. 21st meeting, European Society for Paediatric Infectious Diseases; 2003; Giardini Naxos, Sicily. p 7.
82. Kornelisse RF, Hazelzet JA, Hop WC, et al. Meningococcal septic shock in children: clinical and laboratory features, outcome, and development of a prognostic score. Clin Infect Dis 1997; 25:640-46.
83. Pollack MM, Patel KM, Ruttimann UE. PRISM III: an updated pediatric risk of mortality score. Crit Care Med 1996; 24:743-52.
84. Barbujani G, Magagni A, Minch E, Cavalli-Sforza LL. An apportionment of human DNA diversity. Proc Natl Acad Sci USA 1997; 94:4516-19.